Edition:
United Kingdom

Arsanis Inc (ASNS.OQ)

ASNS.OQ on NASDAQ Stock Exchange Global Market

1.24USD
7:53pm GMT
Change (% chg)

$0.00 (+0.00%)
Prev Close
$1.24
Open
$1.26
Day's High
$1.26
Day's Low
$1.16
Volume
23,865
Avg. Vol
35,463
52-wk High
$27.83
52-wk Low
$1.16

Latest Key Developments (Source: Significant Developments)

Arsanis Q3 Loss Per Share $0.76
Friday, 9 Nov 2018 

Nov 9 (Reuters) - Arsanis Inc ::ARSANIS REPORTS FINANCIAL RESULTS FOR THIRD QUARTER 2018.Q3 LOSS PER SHARE $0.76.ANTICIPATES THAT IT WILL SUBSTANTIALLY COMPLETE IMPLEMENTATION OF REDUCTION IN WORKFORCE BY END OF Q4 OF 2018.ESTIMATES THAT IT WILL INCUR TOTAL EXPENSES OF ABOUT $2.8 MILLION RELATING TO REDUCTION IN WORKFORCE DURING Q4 OF 2018 AND Q1 OF 2019.  Full Article

Arsanis Says Phase 2 Clinical Trial Of ASN100 Unlikely To Meet Primary Efficacy Endpoint
Thursday, 28 Jun 2018 

June 28 (Reuters) - Arsanis Inc ::ARSANIS PROVIDES UPDATE FOLLOWING COMPLETION OF PLANNED INTERIM ANALYSIS OF PHASE 2 CLINICAL TRIAL OF ASN100.TRIAL UNLIKELY TO MEET PRIMARY EFFICACY ENDPOINT; ARSANIS TO CEASE TRIAL ENROLLMENT AND EVALUATE COMPLETE CLINICAL TRIAL DATASET.ARSANIS TO CONTINUE FOCUS ON DEVELOPMENT OF ASN500 FOR PREVENTION OF RSV INFECTION.  Full Article

Arsanis Posts Qtrly Loss Per Share $0.74
Thursday, 10 May 2018 

May 10 (Reuters) - Arsanis Inc ::ASN100 PHASE 2 TRIAL INTERIM ANALYSIS RESULTS EXPECTED IN LATE JUNE.QTRLY LOSS PER SHARE $0.74.AS OF MARCH 31, 2018, OUR CASH AND CASH EQUIVALENTS TOTALED $64.0 MILLION.  Full Article

Arsanis Inc - Out Licenses Preclinical Stage E. Coli Monoclonal Antibodies
Wednesday, 4 Apr 2018 

April 4 (Reuters) - Arsanis Inc ::LICENSES PRECLINICAL STAGE E. COLI MONOCLONAL ANTIBODIES.BB100 SECURED EXCLUSIVE,WORLDWIDE PRECLINICAL DEVELOPMENT LICENSE, OPTION TO DEVELOPMENT, COMMERCIALIZATION LICENSE, TO MABS TARGETING E. COLI.  Full Article

Arsanis Reports Q4 Net Loss $1.68 Per Share
Friday, 9 Mar 2018 

March 9 (Reuters) - Arsanis Inc ::ARSANIS REPORTS FINANCIAL RESULTS AND HIGHLIGHTS FOR FOURTH QUARTER AND FULL YEAR 2017.ARSANIS INC - FOR THE FOURTH QUARTER ENDED DECEMBER 31, 2017, ARSANIS REPORTED NET LOSS OF $1.68 LOSS PER SHARE.ARSANIS INC - AS OF DECEMBER 31, 2017, ARSANIS'S CASH, CASH EQUIVALENTS, MARKETABLE SECURITIES AND INVESTMENTS TOTALED $76.8 MILLION.  Full Article

Arsanis Inc Files To Say It Has Raised $20 Million In Equity Financing - SEC Filing
Monday, 4 Dec 2017 

Dec 4 (Reuters) - Arsanis Inc ::ARSANIS INC FILES TO SAY IT HAS RAISED $20 MILLION IN EQUITY FINANCING - SEC FILING.  Full Article

OrbiMed Advisors Reports 13.07 Percent Stake In Arsanis As Of Nov 20 - SEC Filing ‍​
Thursday, 30 Nov 2017 

Nov 30 (Reuters) - OrbiMed Advisors LLC::ORBIMED ADVISORS LLC REPORTS 13.07 PERCENT STAKE IN ARSANIS INC AS OF NOVEMBER 20 - SEC FILING ‍​.ORBIMED ADVISORS LLC - CAUSED OPI IV TO ACQUIRE COMMON STOCK OF THE ARSANIS INC FOR THE PURPOSE OF MAKING AN INVESTMENT.  Full Article

Terrance G. Mcguire Reports A 13.7 Percent Stake In Arsanis Inc As Of November 20, 2017 - SEC Filig
Wednesday, 29 Nov 2017 

Nov 29 (Reuters) - Arsanis Inc ::TERRANCE G. MCGUIRE REPORTS A 13.7 PERCENT STAKE IN ARSANIS INC AS OF NOVEMBER 20, 2017 - SEC FILIG.  Full Article

New Enterprise Associates 16 L.P. Reports 14.6 Percent Stake In Arsanis As Of Nov 20
Wednesday, 29 Nov 2017 

Nov 29 (Reuters) - NEW ENTERPRISE ASSOCIATES 16 L.P:NEW ENTERPRISE ASSOCIATES 16 L.P. REPORTS A 14.6 PERCENT STAKE IN ARSANIS AS OF NOVEMBER 20, 2017 - SEC FILING.  Full Article

Arsanis Inc shares debut about 30 pct above IPO price‍​
Thursday, 16 Nov 2017 

Nov 16 (Reuters) - :Arsanis Inc shares open at $13.00 in debut on the NASDAQ versus IPO price of $10.00 per share‍​.  Full Article